KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Operating Expenses (2017 - 2025)

Rigel Pharmaceuticals has reported Other Operating Expenses over the past 12 years, most recently at $6.0 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $6.0 million for Q4 2025, up 2.87% from a year ago — trailing twelve months through Dec 2025 was $19.6 million (up 5.22% YoY), and the annual figure for FY2025 was $19.6 million, up 5.22%.
  • Other Operating Expenses for Q4 2025 was $6.0 million at Rigel Pharmaceuticals, up from $4.8 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for RIGL hit a ceiling of $14.5 million in Q4 2022 and a floor of $121000.0 in Q1 2022.
  • Median Other Operating Expenses over the past 5 years was $2.4 million (2024), compared with a mean of $3.3 million.
  • Biggest five-year swings in Other Operating Expenses: soared 1148.6% in 2021 and later plummeted 73.91% in 2023.
  • Rigel Pharmaceuticals' Other Operating Expenses stood at $4.0 million in 2021, then surged by 262.45% to $14.5 million in 2022, then tumbled by 73.91% to $3.8 million in 2023, then skyrocketed by 52.74% to $5.8 million in 2024, then rose by 2.87% to $6.0 million in 2025.
  • The last three reported values for Other Operating Expenses were $6.0 million (Q4 2025), $4.8 million (Q3 2025), and $4.5 million (Q2 2025) per Business Quant data.